Oncology

Prestige Biopharma Plots Biosimilar Growth Strategy

January 20, 2021

Tony Hagen

Article

Biosimilars will be the cornerstone for a leap into biologics development and commercialization, according to the CEO of Prestige Biopharma. Also, Innovent Biologics reaches a marketing agreement.

Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab

January 19, 2021

Tony Hagen

Article

The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18, 2021

Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

IGBA, Celltrion, Others Mark Biosimilar Advances

January 17, 2021

Tony Hagen

Article

The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

With New Policy, CMS Promises to Exit "Stone Age" of Health Information

January 15, 2021

Tony Hagen

Article

CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.

Hill Describes Supercharged Biologics Market in China

January 11, 2021

Tony Hagen

Article

Lawrence A. Hill, PharmD, MBA, RPH, BCPS, provided an insider's view of the rapidly changing biologics and biosimilars market and regulatory structure in China.

Not So Different: Charles Bennett, MD, PhD, Discusses Why the FTC Needs to Join the Effort to Improve the Biosimilar Market

January 10, 2021

Podcast

We spoke to Charles Bennett, MD, PhD, a clinical pharmacy specialist, about his recent oncology biosimilars study and how pay-for-delay schemes have somewhat stalled the biosimilar market.

Data From HERITAGE Confirm PK Biosimilarity for Ogivri

January 9, 2021

Tony Hagen

Article

Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.

Economists Probe Cost-Effectiveness of Biosimilars

January 7, 2021

Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Part 2: Ivo Abraham, PhD, RN, Discusses the Pandemic’s Effect on Pegfilgrastim Biosimilar Use

January 5, 2021

Video

Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice and a health care consultant and co-founder of Matrix45, discussed how the pandemic is likely to impact the use of pegfilgrastim biosimilars.

x